Login to Your Account



Pharma: Clinic roundup


Tuesday, April 29, 2014
Sanofi Pasteur, the vaccines division of Sanofi SA, of Paris, said the first of two pivotal phase III efficacy studies with its dengue vaccine candidate has achieved its primary clinical endpoint. The study showed a reduction of 56 percent of dengue disease cases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription